Leerink Partnrs Comments on Tango Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:TNGX)

Tango Therapeutics, Inc. (NASDAQ:TNGXFree Report) – Research analysts at Leerink Partnrs issued their Q3 2024 earnings per share (EPS) estimates for shares of Tango Therapeutics in a note issued to investors on Monday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.28) for the quarter. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.07) per share. Leerink Partnrs also issued estimates for Tango Therapeutics’ Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($1.16) EPS, FY2025 earnings at ($1.13) EPS and FY2026 earnings at ($1.27) EPS.

Separately, B. Riley assumed coverage on Tango Therapeutics in a research report on Friday, December 8th. They set a “buy” rating and a $16.00 price target on the stock.

Check Out Our Latest Stock Analysis on TNGX

Tango Therapeutics Price Performance

Shares of Tango Therapeutics stock opened at $12.16 on Thursday. The business’s fifty day moving average price is $10.48 and its two-hundred day moving average price is $8.56. The company has a market capitalization of $1.24 billion, a P/E ratio of -10.95 and a beta of 0.95. Tango Therapeutics has a 1-year low of $2.47 and a 1-year high of $13.03.

Tango Therapeutics (NASDAQ:TNGXGet Free Report) last issued its earnings results on Wednesday, November 8th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.11. The company had revenue of $10.73 million during the quarter, compared to analyst estimates of $8.05 million. Tango Therapeutics had a negative return on equity of 41.41% and a negative net margin of 266.73%.

Insider Activity

In other news, CEO Barbara Weber sold 4,681 shares of Tango Therapeutics stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $12.56, for a total transaction of $58,793.36. Following the transaction, the chief executive officer now owns 1,539,624 shares in the company, valued at $19,337,677.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Barbara Weber sold 4,681 shares of Tango Therapeutics stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $12.56, for a total transaction of $58,793.36. Following the completion of the sale, the chief executive officer now owns 1,539,624 shares of the company’s stock, valued at $19,337,677.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Adam Crystal sold 4,288 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $12.56, for a total value of $53,857.28. Following the completion of the sale, the insider now directly owns 123,561 shares of the company’s stock, valued at approximately $1,551,926.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,231 shares of company stock worth $153,703. 6.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tango Therapeutics

Several large investors have recently made changes to their positions in TNGX. Royal Bank of Canada bought a new position in Tango Therapeutics during the first quarter valued at about $32,000. AJOVista LLC bought a new position in Tango Therapeutics during the fourth quarter valued at about $61,000. Cowen AND Company LLC bought a new position in Tango Therapeutics during the fourth quarter valued at about $99,000. Occudo Quantitative Strategies LP bought a new position in Tango Therapeutics during the second quarter valued at about $50,000. Finally, XTX Topco Ltd bought a new position in Tango Therapeutics during the first quarter valued at about $44,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

Recommended Stories

Earnings History and Estimates for Tango Therapeutics (NASDAQ:TNGX)

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.